Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 801–900 of 1,007
Zhuang, H., Fan, J., Li, M., Zhang, H., Yang, X., Lin, L., Lu, S., Wang, Q., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915512 · Cited by 24
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
McFall, T. B., Trogdon, M., Guizar, A. C., Langenheim, J. F., Sisk-Hackworth, L., & Stites, E. C. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00329-w · Cited by 29
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Jy, L., Bhandare, R. R., Boddu, S. H. S., SHAIK, A. B., Saktivel, L. P., Gupta, G., Negi, P., Barakat, M. M., Singh, S. K., Dua, K., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116275 · Cited by 27
Quah, S. Y., Tan, M. S., Teh, Y. H., & Stanslas, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.010 · Cited by 30
Perera, D., & Venkitaraman, A. R. (2016) · Scientific Reports · doi:10.1038/srep29741 · Cited by 26
Tan, L., Cho, K.-J., Neupane, P., Capon, R. J., & Hancock, J. F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003907 · Cited by 23
“Oncogenic mutations that lock RAS in the GTP-bound state occur in 15% of all human cancers, leading to constitutive activation of downstream effectors (1, 2).”
BackgroundAcylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function
Tan, L., Cho, K., Kattan, W. E., Garrido, C. M., Zhou, Y., Neupane, P., Capon, R. J., & Hancock, J. F. (2019) · Journal of Cell Science · doi:10.1242/jcs.232132 · Cited by 23
Wan, Y., Zhang, Y., Wang, G., Mwangi, P. M., Cai, H., & Li, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01326 · Cited by 25
“Unfortunately, KRAS was once considered as an “undruggable” target because it lacks hydrophobic pocket for drugs to bind (1, 8, 9).”
BackgroundKRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas
Hosaka, K., Andersson, P., Wu, J., He, X., Du, Q., Xu, J., Seki, T., Gao, J., Zhang, Y., Sun, X., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303740120 · Cited by 27
“Moreover, although our current findings are focused on KRAS mutations, simultaneous targeting of VEGF and ANG2 for effective antiangiogenic therapy may also apply to other cancer types with HRAS or NRAS mutations.”
InfluentialTargeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 28
“It also presents a catalytic domain (G domain), which binds guanine nucleotides and activates signaling, and a C-terminal hypervariable region (HVR), which binds prenyl or farnesyl groups to drive the anchoring of KRAS to the membrane [21, 22].”
Huang, D. S., Manoni, F., Sun, Z., Liu, R., Allen, J. R., Banerjee, A., Cee, V. J., Eshon, J., Frohn, M. J., Kaller, M. R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03071 · Cited by 23
Emerging role of chemoprotective agents in the dynamic shaping of plasma membrane organization
Fuentes, N. R., Salinas, M. L., Kim, E., & Chapkin, R. S. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.03.014 · Cited by 24
Jin, J. R., Gogvadze, E. V., Xavier, A. R., Bohnacker, T., Völzmann, J., & Wymann, M. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585070 · Cited by 22
“Overall, clinical translation of prenylation inhibitors to mast cell targeted therapy is currently complicated by insufficient potency and side-effects of FTIs and GGTIs in clinical trials (64).”
BackgroundSantha, S., Ling, X., Aljahdali, I. A. M., Rasam, S. S., Wang, X., Liao, J., Wang, J., Fountzilas, C. K., Li, Q., Qu, J., et al. (2020) · Cancers · doi:10.3390/cancers12113413 · Cited by 22
Xiao, X., Lai, M., Song, Z., Geng, M., Ding, J., Xie, H., & Zhang, A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113082 · Cited by 22
Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse
Lee, J.-S., Lee, H., Woo, S. M., Jang, H., Jeon, Y., Kim, H. Y., Song, J., Lee, W. J., Hong, E. K., Park, S.-J., et al. (2021) · Theranostics · doi:10.7150/thno.53935 · Cited by 26
“Therefore, PDAC shows RAS depended metabolic profiles, which accelerates glycolysis by induction of GLUT1, HK1, PFK1 and LDHA as well as pentose phosphate pathway by induction of RPE and RPIA [13, 14].”
BackgroundSilencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA
Papke, B., Azam, S. H., Feng, A. Y., Gutierrez-Ford, C., Huggins, H., Pallan, P. S., Van Swearingen, A. E. D., Egli, M., Cox, A. D., Der, C. J., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00165 · Cited by 22
Self-citationLi, L., Zhao, H., Liao, H., Chen, J., Liu, J., & Chen, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104825 · Cited by 22
Emerging RAS-directed therapies for cancer
Conroy, M. R., Cowzer, D., Kölch, W., & Duffy, A. G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.07 · Cited by 26
Zhang, X., Hong, K., Sun, Q., Zhu, Y., & Du, J. (2021) · Biomaterials Science · doi:10.1039/d1bm00643f · Cited by 22
Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC
Zhang, Y., Guo, R., Li, J., & Zhu, L. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02178-z · Cited by 21
“RAS mutations occur in nearly 30% of lung cancer cases and show a significant correlation with poor prognosis (Cox et al. 2014; Román et al. 2018).”
BackgroundThe promise of signal transduction in genetically driven sarcomas of the nerve
Kim, A., & Pratilas, C. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.014 · Cited by 24
Burmi, R. S., Maginn, E. N., Gabra, H., Stronach, E. A., & Wasan, H. S. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1504718 · Cited by 23
“Although this has largely been hampered by the lack of identification of key actionable pathogenic drivers in PDAC, there has recently been progress in understanding the genetic signature of PDAC, which should lead to new therapies.3-7 It is well documented that the KRAS gene is mutated in ~ 90% of PDAC and is thought…”
BackgroundMethionine 170 is an Environmentally Sensitive Membrane Anchor in the Disordered HVR of K-Ras4B
Neale, C., & García, A. E. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b07919 · Cited by 20
Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses
Akan, D. T., Howes, J. E., Sai, J., Arnold, A. L., Beesetty, Y., Phan, J., Olejniczak, E. T., Waterson, A. G., & Fesik, S. W. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00869 · Cited by 22
Self-citationHe, H., Liu, B., Luo, H., Zhang, T., & Jiang, J. (2020) · Stroke and Vascular Neurology · doi:10.1136/svn-2019-000323 · Cited by 23
“26 MYC is a transcription factor that is involved in a variety of cancer-promoting programs and is often overexpressed in advanced stages of cancer, and various attempts have been made to overcome its lack of medicinally binding pockets.”
BackgroundGagan, G., Lee, D. C., Guye, M. L., Sciver, R. E. V., Lee, P., Lafever, A., Anthony, P., Tang-Tan Angela, M., Winston, J. S., Şamli, B., et al. (2020) · Annals of Breast Cancer and Therapy · doi:10.36959/739/525 · Cited by 25
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy
Wolfson, B., Franks, S. E., & Hodge, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050509 · Cited by 22
“KRAS is the most frequently mutated oncogene in cancer and is a primary driver of pancreatic, colorectal and lung cancers [25].”
BackgroundImproved treatment of nucleosides and nucleotides in the OPLS-AA force field
Robertson, M. J., Tirado‐Rives, J., & Jorgensen, W. L. (2017) · Chemical Physics Letters · doi:10.1016/j.cplett.2017.02.049 · Cited by 25
Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres: Miniperspective
Green, A. I., & Burslem, G. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00592 · Cited by 21
Alexander, P., Chan, A. H., Rabara, D., Swain, M., Larsen, E. K., Dyba, M. D., Chertov, O., Ashraf, M., Champagne, A., Lin, K. Y., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110331 · Cited by 27
“Due to its globular structure and lack of well-de fi ned pockets, KRAS was previously regarded as undruggable (13, 14).”
Searching for the Chokehold of NRAS Mutant Melanoma
Posch, C., Vujic, I., Itzinger-Monshi, B., Sanlorenzo, M., Weihsengruber, F., Rappersberger, K., & Ortiz‐Urda, S. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.006 · Cited by 23
“The four highly homologous members of the RAS protein family neuroblastoma-, Harvey-, and KirstenRAS (NRAS, HRAS, KRAS4A, KRAS4B) are ubiquitously expressed and control cellular proliferation, differentiation, and survival (Cox et al., 2014; Malumbres and Barbacid, 2003).”
BackgroundSciver, R. E. V., Lee, M., Lee, C., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21
“Hyperactivation of the oncogenic K-RAS signaling pathway endows PDAC tumor cells with synergistic compensatory pathway co-activation, increased RAS signaling network plasticity, and genomic and systemic adaptability, culminating in aggressive tumor growth, resistance to cytotoxic agents, systemic metastasis, and poor…”
BackgroundLu, S., Jiang, X., Su, Z., Cui, Z., Fu, W., & Tai, S. (2018) · Cell Biology International · doi:10.1002/cbin.11045 · Cited by 21
“Long non-coding RNA (lncRNA) is a type of non-coding RNA that is greater than 200 nucleotides in length, and is a key regulator in the process of cell transcription (Cox et al., 2014).”
BackgroundOncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
Huynh, M. V., Parsonage, D., Forshaw, T. E., Chirasani, V. R., Hobbs, G. A., Wu, H., Lee, J., Furdui, C. M., Poole, L. B., & Campbell, S. L. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102186 · Cited by 25
“Interestingly, this modification is structurally very similar to aspartic acid, a prevalent oncogenic mutant (KRAS) in human tumors (1, 22).”
BackgroundWolska, A., & Smolewski, P. (2022) · Cancers · doi:10.3390/cancers14153778 · Cited by 22
“Moreover, some, for example RAS oncoproteins, utilize a vast spectrum of substrates and are difficult to modify [51]; as the network of possible interactions and substrates is so great, they are generally believed to be untreatable by conventional approaches.”
BackgroundMechanism-Based Redesign of GAP to Activate Oncogenic Ras
Berta, D., Gehrke, S., Nyíri, K., Vértessy, B. G., & Rosta, E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04330 · Cited by 23
Hu, S., Han, Y., Tan, T.-Y., Chen, H., Gao, J.-W., Wang, L., Yang, M., Zhao, L., Wang, Y., Ding, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167874 · Cited by 27
“Inhibitors targeting epidermal growth factor receptor (EGFR) have been shown to be effective for the treatment of mCRC (4); however, the efficacy of anti-EGFR therapy is often limited by intrinsic drug resistance resulting from downstream KRAS mutation (5, 6).”
BackgroundCaiola, E., Brunelli, L., Marabese, M., Broggini, M., Lupi, M., & Pastorelli, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9849 · Cited by 22
“All attempts to target it directly have failed and KRAS is widely assumed to be undruggable [7].”
The small GTPases Ras and Rheb studied by multidimensional NMR spectroscopy: structure and function
Schöpel, M., Potheraveedu, V. N., Al-Harthy, T. S., Abdel-Jalil, R. J., Heumann, R., & Stoll, R. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0276 · Cited by 23
“Moreover, on the basis of these measurements only, the Ras protein was believed to be undruggable, since it lacks hydrophobic cavities on its molecular surface (Cox et al., 2014).”
InfluentialRecent advances in the biology and therapy of medullary thyroid carcinoma
Nelkin, B. D. (2017) · F1000Research · doi:10.12688/f1000research.12645.1 · Cited by 21
Kim, S., Kim, N., Kang, K., Kim, W., Won, J., & Cho, J. (2019) · Cells · doi:10.3390/cells8080878 · Cited by 21
“Notably, given that no adequate inhibitor targeting mutant RAS is clinically available, there is a high demand for the development of effective therapeutic approaches to treat more than 50% of mCRC patients harboring activating RAS mutations [18,20,21].”
BackgroundTRPML1 and RAS-driven cancers – exploring a link with great therapeutic potential
Jung, J., & Venkatachalam, K. (2019) · Channels · doi:10.1080/19336950.2019.1666457 · Cited by 21
“The paucity of success has even prompted the notion that RAS proteins might be “undruggable” [12,13,15].”
BackgroundYin, G., Zhang, J., Nair, V. V., Truong, V. H., Chaia, A. I., Petela, J., Harrison, J. S., Gorfe, A. A., & Campbell, S. L. (2020) · iScience · doi:10.1016/j.isci.2020.101448 · Cited by 21
The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1
Cai, J., & Yan, G. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.271 · Cited by 23
“37,38 Nonetheless, M1 virus might offer renewed hope for the treatment of cancer with abnormal RAS activation and transform RAS -driven tumors to be ‘‘druggable.’’”
RAS Nanoclusters Selectively Sort Distinct Lipid Headgroups and Acyl Chains
Zhou, Y., Gorfe, A. A., & Hancock, J. F. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.686338 · Cited by 23
“The farnesylated Cys is then methyl-esterified at the α-carboxyl group by isoprenylcysteine carboxyl methyltransferases (ICMT) (Hrycyna et al., 1991; Dai et al., 1998).”
BackgroundSelumetinib in the Treatment of Non-Small-Cell Lung Cancer
Bernabé, R., Patrão, A. S., Carter, L., Blackhall, F. H., & Dean, E. J. (2016) · Future Oncology · doi:10.2217/fon-2016-0132 · Cited by 22
Chen, X., Zou, F., Hu, Z., Du, G., Yu, P., Wang, W., Wang, H., Ye, L., & Tian, J. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115019 · Cited by 20
Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
Krupa, K., Fudalej, M. M., Włoszek, E., Miski, H., Badowska-Kozakiewicz, A. M., Mękal, D., Budzik, M. P., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17152453 · Cited by 25
“KRAS mutations are widespread in PDAC (~85%), colorectal cancer (~45%), and lung adenocarcinoma (~30%), with lower rates in other cancers [28].”
Treatment Individualization in Colorectal Cancer
van Geel, R. M. J. M., Beijnen, J. H., Bernards, R., & Schellens, J. H. M. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0288-z · Cited by 22
“Despite extensive investigation, direct pharmacological inhibition of the KRAS protein remains difficult [32].”
The curious case of Gαs gain-of-function in neoplasia
Innamorati, G., Wilkie, T. M., Kantheti, H. S., Valenti, M. T., Carbonare, L. D., Giacomello, L., Parenti, M. D., Melisi, D., & Bassi, C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4133-z · Cited by 23
“KRAS is one of the most frequently mutated genes in human tumors [37] and its simultaneous expression with gsp is found in certain tumor types.”
BackgroundA H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants
Han, C. W., Jeong, M. S., Ha, S. C., & Jang, S. B. (2020) · Cancers · doi:10.3390/cancers12061412 · Cited by 20
“outstanding issues regarding KRAS could lead to development of effective drugs that have a significant impact on cancer treatment [30].”
BackgroundPadhye, A., Konen, J. M., Rodriguez, B. L., Fradette, J. J., Ochieng, J. K., Diao, L., Wang, J., Lü, W., Solis, L. S., Batra, H., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148392 · Cited by 23
Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood · doi:10.1182/blood.2020010572 · Cited by 20
Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells
Guo, M., He, S., Cheng, J., Li, Y., Dong, G., & Sheng, C. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00670 · Cited by 22
Javaid, S., Schaefer, A., Goodwin, C. M., Nguyen, V. V., Massey, F. L., Pierobon, M., Gambrell-Sanders, D., Waters, A. M., Lambert, K. N., Diehl, J. N., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0142 · Cited by 23
Self-citationXiong, Y., Zeng, J., Xia, F., Cui, Q., Deng, X., & Xu, X. (2022) · Journal of Computational Chemistry · doi:10.1002/jcc.26846 · Cited by 20
Hydrophobic Tag Tethering Degradation, The Emerging Targeted Protein Degradation Strategy
Gao, J., Zhang, J., Han, X., & Zhou, J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220930120328 · Cited by 20
Wang, M., Chen, X., Fu, G., & Ge, M. (2022) · Oncology Reports · doi:10.3892/or.2022.8422 · Cited by 23
“Unlike other druggable aberrations in EGFR and ERBB2, and rearrangements of ALK and RET in lung cancer, KRAS aberrations have been historically described as ‘undruggable’ targets (8).”
BackgroundRetractedAdvancements in Systemic Therapy for Pancreatic Cancer
Brown, T. J., Reiss, K. A., & O’Hara, M. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397082 · Cited by 26
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
Shin, D. H., Jo, J. Y., Choi, M., Kim, K., Bae, Y., & Kim, S. S. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01091-0 · Cited by 22
Xiao, X., Feng, J., Ma, J., Xia, X., Liu, X., Zhang, J., Ding, C., Pang, X., & Zhang, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01724 · Cited by 23
The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv, J., Wang, J., Chang, S., Liu, M., & Pang, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv102 · Cited by 23
Csermely, P., Korcsmáros, T., & Nussinov, R. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.07.005 · Cited by 25
Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation
Ganesan, L., Shieh, P., Bertozzi, C. R., & Levental, I. (2017) · Scientific Reports · doi:10.1038/srep41147 · Cited by 23
The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence
Barnoud, T., Schmidt, M., Donninger, H., & Clark, G. J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.030 · Cited by 27
“Though Ras is mutated in approximately 30% of all human tumors (6), additional cancers contain genetic alterations in Ras regulatory components, such as the Epidermal Growth Factor Receptor (EGFR), Raf, and negative regulators of Ras, such as NF1 (Neurofibromin 1) and DAB2IP (DAB2 Interacting Protein) (7-9).”
New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling
Erickson, K. E., Rukhlenko, O. S., Posner, R. G., Hlavacek, W. S., & Kholodenko, B. N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.008 · Cited by 19
“Recently, methods to inhibit RAS, once thought of as an “undruggable” target, are showing promise [105].”
BackgroundGarcía-Torres, D., & Fierke, C. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007438 · Cited by 22
“One of many efforts to control aberrant GTPase signaling focuses on impeding Ras localization to the plasma membrane by targeting FTase prenylation through small-molecule inhibitors (8).”
BackgroundDonohue, E., Khorsand, S., Mercado, G., Varney, K. M., Wilder, P. T., Yu, W., MacKerell, A. D., Alexander, P., Van, Q. N., Moree, B., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905516116 · Cited by 23
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition
Janardhan, H. P., Meng, X., Dresser, K., Hutchinson, L., & Trivedi, C. M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192205 · Cited by 22
Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition
Brannon, A., Drouillard, D., Steele, N. G., Schoettle, S., Abel, E. V., Crawford, H. C., & di Magliano, M. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-67814-9 · Cited by 19
Inhibition of RAS: proven and potential vulnerabilities
Zuberi, M., Khan, I., & O’Bryan, J. P. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190023 · Cited by 21
Madhyastha, N., Samantha, S. K., Dittakavi, S., Markose, M., Mallurwar, S. R., Zainuddin, M., & Mullangi, R. (2020) · Biomedical Chromatography · doi:10.1002/bmc.5043 · Cited by 20
Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer
Cho, Y. S., Kim, G. C., Lee, H. M., Kim, B., Kim, H. R., Chung, S. W., Chang, H. W., Ko, Y. G., Lee, Y. S., Kim, S. W., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.026 · Cited by 20
Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
Stites, E. C., & Shaw, A. S. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12291 · Cited by 20
Recent advances in the design of small molecular drugs with acrylamides covalent warheads
Liang, L., Zhang, Z., You, Q., & Guo, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117902 · Cited by 23
Luo, Z., Lin, C., Yu, C., Yuan, C., Wu, W., Xu, X., Sun, R., Jia, Y., Wang, Y., Shen, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1093 · Cited by 19
Rahimi, A., Khibech, O., Benabbou, A., Merzouki, M., Bouhrim, M., Al-Zharani, M. M., Nasr, F. A., Qurtam, A. A., Abadi, S., Challioui, A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081110 · Cited by 24
“KRAS mutations drive roughly one-third of all solid tumours [1,2], yet the protein’s shallow, highly polarised surface and picomolar-affinity nucleotide pocket long discouraged classical active-site drug design [3].”
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Zhang, J., Park, D., Shin, D. M., & Deng, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv118 · Cited by 23
The dual role of HMGB1 in pancreatic cancer
Kang, R., & Tang, D. (2018) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000002 · Cited by 20
MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells
Rajabi, H. N., Hata, T., Li, W., Long, M. D., Hu, Q., Liu, S., Raina, D. B., Kui, L., Yasumizu, Y., Hong, D., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0940-1 · Cited by 19
Harnessing Carcinoma Cell Plasticity Mediated by TGF-β Signaling
Wang, X., & Thiery, J. P. (2021) · Cancers · doi:10.3390/cancers13143397 · Cited by 20
Tu, G., Liu, Q., Qiu, Y., Leung, E. L., & Yao, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213845 · Cited by 19
“Since KRAS as one of the most frequently mutated oncogenes, it is mutated in approximately 25% of all human cancers, participating in more than 90% of pancreatic ductal adenocarcinomas (PDAC), approximately 30–40% of colon cancers (CRC), and 17% of non-small cell lung cancer (NSCLC) [3].”
BackgroundQi, W.-L., Li, H.-Y., Wang, Y., Xu, L., Deng, J.-T., Zhang, X., Wang, Y.-X., & Meng, L.-H. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01015-0 · Cited by 19
“KRas acts as a downstream effector of RTK signaling and activates MAPK and PI3K pathways [9, 32].”
BackgroundTargeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Lam, K. K., Wong, S. H., & Cheah, P. Y. (2023) · Cells · doi:10.3390/cells12040631 · Cited by 19
Kazi, A., Ranjan, A., Vasantha Kumar, M. V., Agianian, B., Chavez, M. G., Vudatha, V., Wang, R., Vangipurapu, R., Chen, L., Kennedy, P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0222 · Cited by 17
“However, discovering drugs that could benefitpatientswithcancerwhosetumorsharborKRASG12DandKRASG12V mutations remains a significant unmet need, because the prevalence in human cancers of these mutations is higher than that of KRAS G12C mutations (9).”
BackgroundZeppa, L., Aguzzi, C., Morelli, M. B., Marinelli, O., Giangrossi, M., Luongo, M., Amantini, C., Santoni, G., & Nabissi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042001 · Cited by 22
“While pharmacological approaches to block RAS signaling were clinically unsuccessful, as demonstrated by no clinical benefit of monotherapy in trials [4], efforts are focusing on downstream proteins, such as RAF, MEK, and Akt [5].”
BackgroundMahran, R., Kapp, J. N., Valtonen, S., Champagne, A., Ning, J., Gillette, W., Stephen, A. G., Hao, F., Plückthun, A., Härmä, H., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00315 · Cited by 23
Therapeutic Approaches to RAS Mutation
Scott, A. J., Lieu, C. H., & Messersmith, W. A. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000187 · Cited by 24
Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei
Saarinen, L., Nummela, P., Thiel, A., Lehtonen, R., Järvinen, P., Järvinen, H., Aaltonen, L. A., Lepistö, A., Hautaniemi, S., & Ristimaki, A. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174898 · Cited by 23
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 26
“Such efforts have led RAS to be deemed ‘undruggable’ [154].”
BackgroundInfluentialKrulikas, L. J., McDonald, I. M., Lee, B., Okumu, D. O., East, M. P., Gilbert, T. S. K., Herring, L. E., Golitz, B. T., Wells, C. I., Axtman, A. D., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218773045 · Cited by 21
Does Harvey-Ras gene expression lead to oral squamous cell carcinoma? A clinicopathological aspect
Singh, S., Krishna, A., Singh, V., Kumar, V., Singh, U., & Sankhwar, S. (2018) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_246_17 · Cited by 21
“Moreover, G12V, Q61 R and G13R are reported as predominant mutations in H-Ras gene.[15] A study defined that K‐Ras protein was highly expressed in advance stages of OSCC with higher grade carcinogenesis.”
BackgroundMolecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis
Layfield, L. J., Hammer, R., White, S., Furtado, L. V., & Schmidt, R. L. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0218-oa · Cited by 21
Stewart, A., Coker, E. A., Pölsterl, S., Georgiou, A., Minchom, A. R., Carreira, S., Cunningham, D., O'Brien, M. E. R., Raynaud, F. I., Bono, J. S. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0727 · Cited by 20
“It is known that differences in the type of KRAS mutations between these tumor types do occur, for example, G12C mutations occur more frequently in KRAS NSCLC compared with colorectal cancer (5).”
InfluentialEffects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
Tokumaru, Y., Takabe, K., Yoshida, K., & Akao, Y. (2020) · Cancer Science · doi:10.1111/cas.14357 · Cited by 18
Wiechmann, S., Maisonneuve, P., Grebbin, B. M., Hoffmeister, M., Kaulich, M., Clevers, H. C., Rajalingam, K., Kurinov, I. V., Farin, H. F., Sicheri, F., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011025 · Cited by 20
“Consequently, to date, only a few small-molecule inhibitors exist that directly interfere with Ras function (10).”
BackgroundRuppert, A.-M., Beau‐Faller, M., Debieuvre, D., Ouafik, L., Westeel, V., Rouquette, I., Mazières, J., Bringuier, P., Monnet, I., Escande, F., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100052 · Cited by 22
“” 22 Different clinical trials with selumetinib as MEK inhibitor did not reveal any ef fi cacy in phase 2 or 3 trials.”
BackgroundKhoury, J. D., Tashakori, M., Yang, H. Y., Loghavi, S., Wang, Y., Wang, J., Piya, S., & Borthakur, G. M. (2020) · Cancers · doi:10.3390/cancers12123511 · Cited by 19
“While targeting RAS itself remains elusive in myeloid neoplasms, several inhibitors targeting downstream effectors have been developed in recent years [30].”
BackgroundRetmana, I. A., Loos, N. H. C., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122718 · Cited by 19
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.